Pharmaceuticals were relieved Wednesday after U.S. President Donald Trump revealed they would not be subject to reciprocity tariffs, but such probation could prove short-lived as the White House advanced plans to the industry.

The Trump administration is considering launching what is known as 232 investigations into pharmaceuticals, as well as other industries, which could lead to import tariffs under the Trade Expansion Act.

“Pharmaceutical companies will come back and roar, they are roaring, they are all back in our country because if they don’t, they’re paying a lot of taxes. If they do, I’d be happy.”

In the national emergency declaration that comes with the tariff plan, the White House cited “specially acute” needs to strengthen domestic manufacturing across fields such as drugs, automobiles and shipbuilding.

Healthcare stocks opened slightly higher on Thursday, but the Stoxx Healthcare index then fell 0.4% at 11:00 AM London time, widening the losses from the last meeting as investors improved to increase more uncertainty.

Swiss Luo’s LEDs fell, down 2.4%, while Wegovy-Maker Novo fell 0.7%. Other regional participants, including Nova,,,,, Bavaria Nordic,,,,, AstraZeneca The ticking is slightly higher.

The pharmaceutical industry hopes to gradually disappear scope tariffs after Trump last week. Confirmed Announcements will be coming soon, but drug addicts have been lobbying the government since then A phased approach Allow companies to have time to relocate their manufacturing industries in the United States.

“If the stage approach is achieved, the potential of whispering could weaken the immediate shock of the entire industry,” Citi said in a report on Thursday.

However, even with delayed approaches, the complex nature of the drug supply chain means “a large-scale shift is on a multi-year schedule”, which makes any relief likely to be short-lived.

Novo Nordisk Refuse to comment on the tariff development project Thursday, but Chairman Helge Lund told CNBC last week that the company did not speculate on any tax announcements, but focused on staying “flexible”.

Novo Nordisk already has a large U.S. manufacturing industry, which Lund said is “expanded”, but he will not comment on the U.S. plant sales share, nor will the impact tariffs have on Wegovy drug prices.

Roche said in a statement Thursday that it has a full pharmaceutical and diagnostic value chain in the U.S., where it employs 25,000 employees, but added that it is “considering additional investments to continue to meet the needs of patients.”

British drugmaker Astrazeneca declined to comment ahead of further department-specific announcements.

Meanwhile, Novonesis, a Danish biotech that has a large footprint in the U.S., told CNBC on Tuesday that “uncertainty” around tariff strategies could curb investment and consumer demand.

“It causes uncertainty, and when you are uncertain, you stop. You pause innovation, release release, pause investment,” she said.